Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers

Collection of Tissue, Blood, and Other Specimens From Patients With Head and Neck Diseases to Study the Causes, Diagnosis, Prevention and Treatment of Cancers

NCT00580203•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

This is a protocol to collect tissues, blood, and other specimens from patients with malignant or nonmalignant diseases of the head and neck. Collected specimens will be used in laboratory studies to investigate the growth, development, and transformation of normal and abnormal cells in the future.

Detailed Description

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients will be entered onto this protocol without preference for any racial or ethnic group.
•Patients may have received prior chemotherapy, radiation, surgical therapy, immunotherapy, or differentiation therapy.
•The specimen collected must be large enough to allow conventional testing necessary for patient care, with the portion of the specimen reserved for research laboratory analysis excised from residual tissue that would otherwise have been discarded.

Exclusion Criteria

•Patients not giving informed consent will be excluded.

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Key Dates

Start Date

February 1, 2004

Primary Completion Date

November 12, 2024

Completion Date

November 12, 2024

Last Updated

November 15, 2024

Enrollment

1,468

ACTUAL participants

Conditions

Head and Neck Cancers

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

NCT05526924

Head and Neck CancerHead and Neck Squamous Cell Carcinoma+3 more

View study

RECRUITINGPHASE1

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

NCT06736379

Head and Neck Cancers- Squamous CellHead and Neck Cancer+11 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 15, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers

Inclusion Criteria

Exclusion Criteria

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Head and Neck Cancers Patients

Prospective Evaluation of Frailty in Patients With Head and Neck Tumors Before Curative Intended Therapy

Relaxation Therapy for Pain, Fatigue and Vital Signs in Post-operation With Head and Neck Cancer

Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R